Patents Assigned to E. R. Squibb & Sons
  • Patent number: 10501556
    Abstract: Methods for treating a cocaine-related disorder in an individual include administering to the individual a therapeutic amount of an antibody comprising a human immunoglobulin gamma heavy chain and a murine lambda light chain. In another embodiment, the light chain includes a human kappa light chain at least partially derived from 1B3. Other embodiments are directed toward the antibodies themselves and methods of binding the antibodies.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: December 10, 2019
    Assignees: University of Cincinnati, E. R. Squibb & Sons, L.L.C.
    Inventors: Andrew B. Norman, William J. Ball, Jr., Nils Lonberg, Denise Williams
  • Patent number: 10448622
    Abstract: The present invention relates to a human artificial chromosome which is genetically transmissible to the next generation with high efficiency and the method for using the same. More specifically, the present invention relates to: a human artificial chromosome in which an about 3.5 Mb to about 1 Mb region containing an antibody ? light chain gene derived from human chromosome 22 is bound to a chromosome fragment which is transmissible to a progeny through a germ line of a non-human animal, said chromosome fragment is derived from another human chromosome; a non-human animal carrying the human artificial chromosome and an offspring thereof; a method for producing the non-human animal; a method for producing a human antibody using the nonhuman animal or an offspring thereof; and a human antibody-producing mouse carrying the human artificial chromosome.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: October 22, 2019
    Assignees: E. R. Squibb & Sons, L.L.C., Kyowa Hakko Kirin Co., Ltd
    Inventors: Yoshimi Kuroiwa, Kazuma Tomizuka, Hitoshi Yoshida, Isao Ishida
  • Patent number: 10155813
    Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: December 18, 2018
    Assignee: E. R. Squibb & Sons, L.L.C.
    Inventors: Jennifer Marie Mataraza, Andrea Van Elsas, Alan J. Korman, Edward L. Halk, Kent B. Thudium, Mark J. Selby, Timothy W. Sproul, Heidi N. Leblanc
  • Patent number: 9758593
    Abstract: Methods for treating a cocaine-related disorder in an individual include administering to the individual a therapeutic amount of an antibody comprising a human immunoglobulin gamma heavy chain and a murine lambda light chain. In another embodiment, the light chain includes a human kappa light chain at least partially derived from 1B3. Other embodiments are directed toward the antibodies themselves and methods of binding the antibodies.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: September 12, 2017
    Assignees: University of Cincinnati, E. R. Squibb & Sons, L.L.C.
    Inventors: Andrew B. Norman, William J. Ball, Jr., Nils Lonberg, Denise Williams
  • Patent number: 9505845
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.
    Type: Grant
    Filed: April 9, 2012
    Date of Patent: November 29, 2016
    Assignee: E. R. Squibb & Sons, L.L.C.
    Inventors: Jonathan Alexander Terrett, Li-Sheng Lu, Chin Pan
  • Patent number: 9273135
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-LI antibodies.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: March 1, 2016
    Assignee: E. R. Squibb & Sons, L. L. C.
    Inventors: Alan J. Korman, Mark J. Selby, Changyu Wang, Mohan Srinivasan, David B. Passmore, Haichun Huang, Haibin Chen
  • Patent number: 9260514
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of these antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: February 16, 2016
    Assignees: Amgen Inc., E. R. Squibb & Sons, L.L.C.
    Inventors: Kenneth D. Wild, Jr., James J.S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
  • Patent number: 9138475
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: September 22, 2015
    Assignee: E. R. Squibb & Sons, L.L.C.
    Inventors: Cynthia A. Vistica, Eric H. Holmes, Peter Brams, Alison Witte, Josephine M. Cardarelli
  • Patent number: 9102738
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: August 11, 2015
    Assignee: E. R. Squibb & Sons, L.L.C.
    Inventors: Jonathan Alexander Terrett, Li-Sheng Lu, Chin Pan
  • Patent number: 6551794
    Abstract: Stable compositions containing biotinylated molecules, such as enzymes, are provided. The compositions include a biotinylated biomolecule, a biomolecule protectant, a buffer, a bulking agent selected from one or more water soluble, nonionic polymers and preferably a terminal sterilization protectant. The compositions can be utilized either as aqueous solutions or preferably in dried form, e.g., as a lyophilized, powder cake. They have applicability in any case where avidin/biotin technology is used and are particularly important as compositions containing a thrombin-like enzyme, e.g., for preparation of a fibrin monomer and fibrin monomer-based fibrin sealants.
    Type: Grant
    Filed: November 9, 1995
    Date of Patent: April 22, 2003
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Steven James Burton, James C. Pearson, Peter A. D. Edwardson, Alan Menzies
  • Patent number: 6387082
    Abstract: An ostomy appliance or wound drainage device having a receptacle side component including a receptacle for receiving and storing waste solids and fluids and a bodyside component for adhering to the patient's skin around the stoma in which the two components are releasably sealed together through a pealable, washable based coupling mechanism.
    Type: Grant
    Filed: September 1, 1999
    Date of Patent: May 14, 2002
    Assignee: E. R. Squibb & Sons, Inc.
    Inventor: Frank Freeman
  • Patent number: 6284285
    Abstract: A method for isolating tissue repair promoting substances from human or animal blood, which method comprises collecting the human or animal blood from a single human or animal individual in a first container of a container system comprising at least first and second interconnected containers; centrifuging the container system containing said blood so as to separate the blood in various fractions including a plasma fraction; transferring at least part of the plasma fraction to said second container of the container system; subjecting the plasma fraction in said second container to a low temperature so as to obtain a precipitate comprising tissue repair promoting substances; concentrating said precipitate in said second container so as to obtain a first fraction comprising a major part of the non-precipitated material, and a second fraction comprising at least the major part of the precipitate and a minor part of the non-precipitated material; and separating said second fraction comprising the tissue repair pro
    Type: Grant
    Filed: December 29, 1992
    Date of Patent: September 4, 2001
    Assignee: E. R. Squibb & Sons, Inc.
    Inventor: Ulla Sivertsen Weis-Fogh
  • Patent number: 6117885
    Abstract: Compounds of the formula ##STR1## wherein X, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, A, B, D and E are as defined herein. These compounds inhibit the action of angiotensin II and are useful, therefore, for example, as antihypertensive agents.
    Type: Grant
    Filed: February 24, 1994
    Date of Patent: September 12, 2000
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Denis Evan Ryono, John Lloyd
  • Patent number: 6087349
    Abstract: A method is provided by blocking or preventing the prenylation of CAAX box containing proteins including ras oncogene products thereby preventing and/or treating ras-related tumors which includes the step of administering a therapeutically effective amount of a protein-prenyl transferase inhibitor.
    Type: Grant
    Filed: May 6, 1998
    Date of Patent: July 11, 2000
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Scott A. Biller, Mariano Barbacid, Eric M. Gordon, David R. Magnin, Chester A. Meyers, Veeraswamy Manne
  • Patent number: 6066773
    Abstract: A thin film device for medical applications such as a wound dressing including an occlusive layer having an edge portion about at least a portion of the thin film device and a non-continuous, hydrocolloid-containing polymeric support layer overlying the edge portion of the occlusive layer.
    Type: Grant
    Filed: August 25, 1995
    Date of Patent: May 23, 2000
    Assignee: E. R. Squibb & Sons, Inc.
    Inventor: Frank Freeman
  • Patent number: 6046024
    Abstract: Compositions and methods for avidin immobilized on an inert support material, e.g. agarose, are disclosed. The compositions have high activity levels of avidin and may further include a bulking agent, e.g., maltose, and a protectant to maintain the stability and integrity of the avidin agarose during lyophilization and terminal sterilization processes. These compositions have applicability in any instance where avidin agarose and/or the avidin/biotin technology are useful. In particular, the present compositions are useful in an enzyme capture system to prepare fibrin monomer useful for fibrin sealants. The fibrin is prepared by subjecting a fibrinogen-containing composition to a biotinylated enzyme to convert the fibrinogen in the composition to a corresponding fibrin monomer. A fibrin monomer/biotinylated enzyme mixture is formed.
    Type: Grant
    Filed: August 1, 1997
    Date of Patent: April 4, 2000
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Steven James Burton, James C. Pearson, Peter A. D. Edwardson
  • Patent number: 6030794
    Abstract: The present invention provides mice which are deficient in the normal expression of one or more members of the RAR or RXR class of receptors, mice which are heterozygous for such deficiency, and to cell lines, preferably pluripotent or totipotent cell lines, which are heterozygous or homozygous for such deficiency. The present invention further provides the use of any of the above mice and cell lines in situations where the absence of at least one RAR or RXR receptor(s), or the normal expression thereof, is desirable.
    Type: Grant
    Filed: June 27, 1995
    Date of Patent: February 29, 2000
    Assignees: Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite Louis Pasteur, E. R. Squibb & Sons, Inc.
    Inventors: Pierre Chambon, Thomas Lufkin, David Lohnes, Manuel Mark, Andree Dierich, Philippe Gorry, Philippe Kastner, Marianne Lemeur, Cathy Mendelsohn
  • Patent number: 5968024
    Abstract: An ostomy appliance or wound drainage device having a lower end with an adhesive composition thereon so that when the lower end is folded upon itself, the drainage opening is closed off, or, alternatively, the lower end is made of a material having intrinsic adhesive properties.
    Type: Grant
    Filed: February 24, 1998
    Date of Patent: October 19, 1999
    Assignee: E. R. Squibb & Sons, Inc.
    Inventor: Frank Freeman
  • Patent number: 5942406
    Abstract: Compositions and methods for avidin immobilized on an inert support material, e.g., agarose, are disclosed. The compositions have high activity levels of avidin and may further include a bulking agent, e.g., maltose, and a protectant to maintain the stability and integrity of the avidin agarose during lyophilization and terminal sterilization processes. A dry composition, and wet compositions such as a gel, slurry or suspension having avidin immobilized on an inert support material are disclosed. The dry composition has at least 1000 biotin binding units of activity, and the wet compositions have at least 50 units of binding activity. These compositions have applicability in any instance where avidin agarose and/or the avidin/biotin technology are useful. In particular, the present compositions are useful in an enzyme capture system to prepare fibrin monomer useful for fibrin sealants.
    Type: Grant
    Filed: August 1, 1997
    Date of Patent: August 24, 1999
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Steven James Burton, James C. Pearson, Peter A. D. Edwardson
  • Patent number: 5859239
    Abstract: Compounds of the formula ##STR1## wherein X.sub.1 is ##STR2## are disclosed. These compounds possess inhibitory activity against angiotensin converting enzyme and neutral endopeptidase and thus useful as cardiovascular agents.
    Type: Grant
    Filed: September 30, 1997
    Date of Patent: January 12, 1999
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Donald S. Karanewsky, Jeffrey A. Robl